Kindred Biosciences, Inc.
KIN
KIN was delisted on the 27th of August, 2021.
63 hedge funds and large institutions have $153M invested in Kindred Biosciences, Inc. in 2018 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 24 reducing their positions, and 6 closing their positions.
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
3% more funds holding
Funds holding: 61 → 63 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less capital invested
Capital invested by funds: $171M → $153M (-$18.6M)
38% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 24
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $484K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BRF
B. Riley Financial
Los Angeles,
California
|
+$1.14M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$907K |
| 3 |
PVAM
Pacific View Asset Management
San Francisco,
California
|
+$479K |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$340K |
| 5 |
Citigroup
New York
|
+$262K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.6M |
| 2 |
AI
Ariel Investments
Chicago,
Illinois
|
-$1.7M |
| 3 |
GIP
Granite Investment Partners
El Segundo,
California
|
-$872K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$822K |
| 5 |
AFS
Amtrust Financial Services
New York
|
-$621K |
KIN Hedge Fund Activity: Q1 2018 in Review
63 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Kindred Biosciences, Inc. (KIN) for Q1 2018, worth a combined $153M — down 11% from $171M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new KIN positions and 6 closed out — a net gain of 2 holders — while 15 added to existing stakes and 24 trimmed.
The largest buyer was B. Riley Financial, opening a new position worth an estimated $1.14M. The largest seller was EcoR1 Capital, cutting an estimated $2.6M.
- 63 institutional investors held Kindred Biosciences, Inc. (KIN) as of Q1 2018, up from 61 in Q4 2017.
- Funds reported $153M of Kindred Biosciences, Inc. stock for Q1 2018, down 11% quarter-over-quarter.
- 8 funds opened new Kindred Biosciences, Inc. positions in Q1 2018 and 6 closed out, a net change of +2 holders.
- The largest Kindred Biosciences, Inc. buyer in Q1 2018 was B. Riley Financial, an estimated $1.14M added.
- The largest Kindred Biosciences, Inc. seller in Q1 2018 was EcoR1 Capital, an estimated $2.6M sold.
Based on aggregated 13F filings for Q1 2018.